Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
China Resources Pharmaceutical Group has disclosed the unaudited first-quarter 2026 financial results of its subsidiary KPC Pharmaceuticals, which showed a sharp deterioration in performance. KPC’s revenue fell to RMB836.2 million from RMB1.61 billion a year earlier, flipping from a net profit of RMB113.6 million to a net loss of RMB144.8 million, while cash and cash equivalents dropped to RMB389.4 million amid a net cash outflow of RMB741.6 million.
KPC’s balance sheet also weakened slightly, with total assets edging down to RMB11.22 billion and owner’s equity slipping to RMB6.80 billion as of 31 March 2026, compared with year-end 2025 levels. The parent group stressed that these figures, prepared under PRC accounting standards and not yet audited, pertain solely to KPC and do not fully reflect the overall financial condition of China Resources Pharmaceutical, urging shareholders and investors to exercise caution when assessing the impact on the wider group.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated healthcare conglomerate with a broad portfolio spanning pharmaceutical manufacturing, distribution and medical services. Through its non-wholly-owned subsidiary China Resources Sanjiu Medical & Pharmaceutical, it holds a controlling stake of about 28.05% in KPC Pharmaceuticals, a Shanghai-listed drug maker in mainland China, integrating upstream production with its wider group operations.
Average Trading Volume: 18,740,562
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$36.69B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.